23andMe Lowers Price Again, Ends Subscriptions
May 11, 2012
Price to Explore Your Own DNA Has Dropped from $999 to $299 in Just Five Years
Mountain View, Calif. – May 11, 2012 – 23andMe, a leading personal genetics company, today restructured pricing in order to help more individuals explore their own DNA and participate directly in research. Effective today, 23andMe will offer its Personal Genome Service® for just $299 – a $100 reduction in price and a drop of $700 since the service first launched in 2007. 23andMe’s Personal Genome Service® enables individuals to explore their own DNA and provides more than 200 health and traits reports as well as genetic ancestry information. When the service first launched five years ago, it cost $999 and provided just 14 reports. The company is now offering its Personal Genome Service® for a simple single payment, ending its subscription pricing options effective today. Subscription customers who’ve fulfilled their initial contract commitment will simply no longer need to pay a monthly fee while continuing to enjoy their Personal Genome Service®. “We’ve explored many pricing structures to make our service as accessible as possible,” said Anne Wojcicki, 23andMe CEO. “We concluded, a single price model without subscriptions is the best option for both 23andMe and for our customers.” In addition to adjusting its pricing structure, the company has also focused on improving operational efficiencies. As a result, the company is now able to provide customers with their initial genetic analysis within just two to three weeks, reducing laboratory-processing time by more than a month. “Once an individual decides to be a customer, we want to get them their data as quickly as possible. Getting customers their data fast is a high priority,” noted Wojcicki. An ongoing service, 23andMe’s Personal Genome Service® provides a wealth of information about an individual’s DNA and updates about new research. Customers can also choose to participate in the company’s unique research programs. By completing online surveys, customers contribute directly to genetic research that can potentially lead to better understanding of and new treatments for a variety of health conditions. To learn more, visit www.23andMe.com
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.